动物造模,孤独症模型 z-bio 2022-11-24 260

　　Objective: To investigate the effect of sulindac on the behavior of autistic rats.

　　Methods: The autistic rat model was established by intraperitoneal injection of sodium valproate (VPA) 12.5 days after pregnancy. For the sulindac treatment group, rats were orally given 20 mg/kg sulindac every day after VPA injection until weaning. The newborn rats were divided into four groups: control group, VPA treatment group, sulindac treatment group and VPA combined sulindac treatment group. On the 35th day after birth, the social interaction behavior and open box anxiety like behavior of young rats were detected, and the brain tissue proteins were isolated and extracted to analyze the key proteins of Wnt signaling pathway with Western blot β- Catenin and Gsk3 β Express the situation.

　　Results: The rat model of autism was successfully established. Compared with the control group, the VPA treatment group had decreased social interaction ability, increased activity time in the central area, and decreased standing times, which was consistent with the behavioral characteristics of autism; There was no significant behavioral change in sulindac group alone; However, sulindac combined treatment can significantly improve the behavioral symptoms of autism caused by VPA treatment. Western blot results showed that VPA treatment could enhance the expression of β- Catenin expression level and decrease Gsk3 β Serine phosphorylation level at position 9; However, sulindac combined treatment can inhibit β- Catenin expression level and increase Gsk3 β Serine phosphorylation level at position 9.

　　Conclusion: Sulindac can improve the behavior of autism model rats, and the mechanism may be related to the inhibition of Wnt signal pathway in brain tissue.